{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:41:51Z","timestamp":1791607311106,"version":"4.3.4"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:sec id=\"ab-coi240054-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Previous studies showed that 42% to 50% of patients with locally advanced hepatocellular carcinoma (HCC) achieved complete remission (CR) after combined locoregional therapy (LRT) plus immunotherapy (IO). However, data on predictors of CR and long-term clinical outcomes without surgery and after discontinuation of IO are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi240054-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the long-term clinical outcomes among patients with unresectable HCC who achieved CR after LRT-IO and were placed on a watch-and-wait protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi240054-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cohort study included patients with unresectable HCC who achieved CR after LRT-IO in 2 prospective studies between January 2018 and December 2022. The time of data cutoff was June 2023. Radiologic CR was defined per modified Response Evaluation Criteria in Solid Tumors. All patients underwent close surveillance after CR without surgical interventions, and IO was discontinued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi240054-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>All patients had received stereotactic body radiotherapy followed by anti\u2013programmed cell death protein 1 or anti\u2013programmed death ligand 1 therapy. Forty-nine patients had received a dose of transarterial chemoembolization before stereotactic body radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi240054-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was the 3-year overall survival (OS) rate. Secondary outcomes included the 3-year time-to-progression rate, 3-year local control rate, and relapse pattern. Factors associated with CR were analyzed using multivariate analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi240054-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 63 patients were enrolled (58 male [92.1%]; median age, 69 years [range, 18-90 years]); 38 patients (60.3%) had macrovascular invasion, and the median tumor diameter was 10 cm (range, 3.8-31.1 cm). The median follow-up time was 34.7 months (95% CI, 6.5-64.6 months). Twenty-nine patients (46.0%) achieved CR. The patients achieving CR had a significantly better 3-year OS rate than patients not achieving CR (75.5% [95% CI, 58.2%-98.3%] vs 28.1% [95% CI, 7.4%-29.4%];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Among the 29 patients with CR, the 3-year time-to-progression rate was 58.7% (95% CI, 38.7%-79.1%) and the 3-year local control rate was 90.5% (95% CI, 78.2%-100%). Ten patients (34.5%) developed recurrence; among them, 6 (60.0%) with solitary intrahepatic disease relapse underwent curative surgical treatment. The absence of tumor vascular invasion (odds ratio, 0.30; 95% CI, 0.10-0.89) and the sum of the largest lesion diameters of 8 cm or less (odds ratio, 0.26; 95% CI, 0.07-0.98) were associated with CR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi240054-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This cohort study of LRT-IO with long-term follow-up data found a durable response in patients with locally advanced unresectable HCC. Long-term survival was attainable in patients with radiologic CR. Further randomized clinical trials are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.4085","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T11:56:42Z","timestamp":1727351802000},"page":"1548","source":"Crossref","is-referenced-by-count":42,"title":["Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma"],"prefix":"10.1001","volume":"10","author":[{"given":"Chi Leung","family":"Chiang","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong and University of Hong Kong\u2013Shenzhen Hospital, Hong Kong, China"},{"name":"State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth Sik Kwan","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith Wan Hang","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"name":"Department of Diagnostic and Interventional Radiology, Kwong Wah Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Ann Shing","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Oncology Center, University of Hong Kong\u2013Shenzhen Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie Sean Man","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan Lok Man","family":"Ho","sequence":"additional","affiliation":[{"name":"Radiotherapy and Oncology Department, Gleneagles Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venus Wan Yan","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical Physics Unit, Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan","family":"Man","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng Ming (Spring)","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong and University of Hong Kong\u2013Shenzhen Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Chi Yan","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"name":"State Key Laboratory of Liver Research, University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi240054r1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"coi240054r2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000514313","article-title":"Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations.","volume":"10","author":"Zhu","year":"2021","journal-title":"Liver Cancer"},{"issue":"20","key":"coi240054r3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"coi240054r4","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"5","key":"coi240054r5","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s12072-022-10396-7","article-title":"Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial.","volume":"16","author":"Li","year":"2022","journal-title":"Hepatol Int"},{"issue":"12","key":"coi240054r6","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","article-title":"Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.","volume":"6","author":"Tai","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"coi240054r7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.798832","article-title":"Combined stereotactic body radiotherapy and immunotherapy versus transarterial chemoembolization in locally advanced hepatocellular carcinoma: a propensity score matching analysis.","volume":"11","author":"Chiang","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"coi240054r8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial.","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"coi240054r9","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2019.01.027","article-title":"Combined locoregional-immunotherapy for liver cancer.","volume":"70","author":"Greten","year":"2019","journal-title":"J Hepatol"},{"key":"coi240054r10","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"issue":"11","key":"coi240054r11","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41571-019-0277-2","article-title":"Combining immunotherapy and radiotherapy for the STAR treatment.","volume":"16","author":"Torok","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"coi240054r12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/SLA.0000000000004930","article-title":"Chemoradiotherapy followed by active surveillance versus standard esophagectomy for esophageal cancer: a systematic review and individual patient data meta-analysis.","volume":"275","author":"van der Wilk","year":"2022","journal-title":"Ann Surg"},{"issue":"10139","key":"coi240054r13","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.","volume":"391","author":"van der Valk","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"coi240054r14","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/hep4.1923","article-title":"Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies.","volume":"6","author":"Reveron-Thornton","year":"2022","journal-title":"Hepatol Commun"},{"issue":"3","key":"coi240054r15","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/hep.29883","article-title":"Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies.","volume":"68","author":"Hyun","year":"2018","journal-title":"Hepatology"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2824197\/jamaoncology_chiang_2024_oi_240054_1732041440.16826.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T11:01:17Z","timestamp":1732186877000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2824197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.4085","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}